Display options
Cite
Shailubhai K, Palejwala V, Arjunan KP, et al. Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis. World J Gastrointest Pharmacol Ther. 2015;6(4):213-22doi: 10.4292/wjgpt.v6.i4.213.
Shailubhai, K., Palejwala, V., Arjunan, K. P., Saykhedkar, S., Nefsky, B., Foss, J. A., Comiskey, S., Jacob, G. S., & Plevy, S. E. (2015). Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis. World journal of gastrointestinal pharmacology and therapeutics, 6(4), 213-22. https://doi.org/10.4292/wjgpt.v6.i4.213
Shailubhai, Kunwar, et al. "Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis." World journal of gastrointestinal pharmacology and therapeutics vol. 6,4 (2015): 213-22. doi: https://doi.org/10.4292/wjgpt.v6.i4.213
Shailubhai K, Palejwala V, Arjunan KP, Saykhedkar S, Nefsky B, Foss JA, Comiskey S, Jacob GS, Plevy SE. Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis. World J Gastrointest Pharmacol Ther. 2015 Nov 06;6(4):213-22. doi: 10.4292/wjgpt.v6.i4.213. PMID: 26558155; PMCID: PMC4635161.
Copy Download .nbib Format: NLM
Share it on

World J Gastrointest Pharmacol Ther. 2015 Nov 06;6(4):213-22. doi: 10.4292/wjgpt.v6.i4.213.

Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis.

World journal of gastrointestinal pharmacology and therapeutics

Kunwar Shailubhai, Vaseem Palejwala, Krishna Priya Arjunan, Sayali Saykhedkar, Bradley Nefsky, John A Foss, Stephen Comiskey, Gary S Jacob, Scott E Plevy

Affiliations

  1. Kunwar Shailubhai, Vaseem Palejwala, John A Foss, Stephen Comiskey, R and D Center, Synergy Pharmaceuticals Inc., Doylestown, PA 18902, United States.

PMID: 26558155 PMCID: PMC4635161 DOI: 10.4292/wjgpt.v6.i4.213

Abstract

AIM: To evaluate the effect of orally administered plecanatide or dolcanatide, analogs of uroguanylin, on amelioration of colitis in murine models.

METHODS: The cyclic guanosine monophosphate (cGMP) stimulatory potency of plecanatide and dolcanatide was measured using a human colon carcinoma T84 cell-based assay. For animal studies all test agents were formulated in phosphate buffered saline. Sulfasalazine or 5-amino salicylic acid (5-ASA) served as positive controls. Effect of oral treatment with test agents on amelioration of acute colitis induced either by dextran sulfate sodium (DSS) in drinking water or by rectal instillation of trinitrobenzene sulfonic (TNBS) acid, was examined in BALB/c and/or BDF1 mice. Additionally, the effect of orally administered plecanatide on the spontaneous colitis in T-cell receptor alpha knockout (TCRα(-/-)) mice was also examined. Amelioration of colitis was assessed by monitoring severity of colitis, disease activity index and by histopathology. Frozen colon tissues were used to measure myeloperoxidase activity.

RESULTS: Plecanatide and dolcanatide are structurally related analogs of uroguanylin, which is an endogenous ligand of guanylate cyclase-C (GC-C). As expected from the agonists of GC-C, both plecanatide and dolcanatide exhibited potent cGMP-stimulatory activity in T84 cells. Once-daily treatment by oral gavage with either of these analogs (0.05-0.5 mg/kg) ameliorated colitis in both DSS and TNBS-induced models of acute colitis, as assessed by body weight, reduction in colitis severity (P < 0.05) and disease activity index (P < 0.05). Amelioration of colitis by either of the drug candidates was comparable to that achieved by orally administered sulfasalazine or 5-ASA. Plecanatide also effectively ameliorated colitis in TCRα(-/-) mice, a model of spontaneous colitis. As dolcanatide exhibited higher resistance to proteolysis in simulated gastric and intestinal juices, it was selected for further studies.

CONCLUSION: This is the first-ever study reporting the therapeutic utility of GC-C agonists as a new class of orally delivered and mucosally active drug candidates for the treatment of inflammatory bowel diseases.

Keywords: Dolcanatide; Guanylate cyclase-C; Inflammatory bowel disease; Plecanatide; Uroguanylin

References

  1. Biochem Biophys Res Commun. 2005 Feb 4;327(1):106-11 - PubMed
  2. J Clin Gastroenterol. 1992;14 Suppl 1:S29-33 - PubMed
  3. J Exp Med. 2005 Dec 19;202(12 ):1703-13 - PubMed
  4. Gastroenterology. 1984 Dec;87(6):1344-50 - PubMed
  5. Pharmacol Ther. 2004 Nov;104(2):137-62 - PubMed
  6. J Immunol. 2011 May 1;186(9):5506-13 - PubMed
  7. Gastroenterology. 2002 May;122(6):1592-608 - PubMed
  8. Expert Rev Clin Pharmacol. 2013 Sep;6(5):557-64 - PubMed
  9. J Leukoc Biol. 2009 Sep;86(3):633-43 - PubMed
  10. Am J Physiol. 1997 Jul;273(1 Pt 1):G93-105 - PubMed
  11. Cancer Res. 2000 Sep 15;60(18):5151-7 - PubMed
  12. Inflamm Bowel Dis. 2007 Jul;13(7):807-21 - PubMed
  13. Clin Pharmacol Ther. 2007 Oct;82(4):441-7 - PubMed
  14. PLoS One. 2013 Nov 11;8(11):e79180 - PubMed
  15. Lancet. 2012 Nov 3;380(9853):1606-19 - PubMed
  16. J Immunol. 2011 Jun 15;186(12):7205-14 - PubMed
  17. Am J Pathol. 2007 Dec;171(6):1847-58 - PubMed
  18. Endocrinology. 2007 Jan;148(1):332-6 - PubMed
  19. Gastroenterology. 2005 Aug;129(2):550-64 - PubMed
  20. Mol Cell Biochem. 2010 Jan;334(1-2):67-80 - PubMed
  21. Curr Gastroenterol Rep. 2004 Dec;6(6):488-95 - PubMed
  22. Nat Rev Immunol. 2011 Aug 26;11(10):636-7 - PubMed
  23. PLoS One. 2010 Jan 05;5(1):e8584 - PubMed
  24. Nature. 2007 Jul 26;448(7152):427-34 - PubMed
  25. Gastroenterology. 2011 May;140(6):1807-16 - PubMed
  26. J Gastroenterol. 2010 Jun;45(6):571-83 - PubMed
  27. Clin Exp Immunol. 1999 Sep;117(3):462-8 - PubMed
  28. PLoS One. 2011 Jan 31;6(1):e16139 - PubMed
  29. Dig Dis Sci. 2013 Sep;58(9):2580-6 - PubMed
  30. Gastroenterol Clin North Am. 2002 Mar;31(1):1-20 - PubMed
  31. Curr Opin Drug Discov Devel. 2002 Mar;5(2):261-8 - PubMed
  32. Physiol Genomics. 2012 Apr 2;44(7):430-42 - PubMed
  33. Curr Opin Gastroenterol. 2014 Jan;30(1):1-6 - PubMed
  34. Lab Invest. 1998 Jan;78(1):101-8 - PubMed
  35. J Clin Invest. 1996 Aug 15;98(4):1010-20 - PubMed
  36. PLoS One. 2012;7(2):e31686 - PubMed
  37. Transl Res. 2007 Apr;149(4):173-86 - PubMed

Publication Types